Drug intelligence / Profile preview

pentazocine + naloxone

Development stage
Discontinued
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Pentazocine + naloxone is an oral combination analgesic used for the management of moderate to severe pain when alternative treatments are inadequate. It contains two active ingredients:\n- **Pentazocine** is a partial opioid agonist that acts on opioid receptors in the brain and nervous system to alter pain perception, providing analgesia.\n- **Naloxone** is an opioid antagonist included at a low dose (0.5 mg per tablet) that has no significant effect when taken orally but blocks opioid effects if the medication is misused by injection, thereby deterring abuse.\n\nThe combination provides effective pain relief while reducing the risk of misuse associated with opioids. The typical formulation contains 50 mg pentazocine and 0.5 mg naloxone per tablet[1][2][4][5][6].

Brand names
Talwin NX
Other names
pentazocine and naloxonepentazocine/naloxone
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on pentazocine + naloxone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pentazocine + naloxone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call